Global Menopausal Hot Flashes Market Drivers 2024, Forecast To 2033
8 Mar, 2024
Menopausal hot flashes market advanced from $14.06 billion in 2023 to $14.99 billion in 2024, with a 6.6% CAGR due to hormone replacement therapy. Growth to $18.75 billion in 2028 (CAGR: 5.8%) is expected, with trends focusing on non-pharmacological interventions and digital health solutions.
Global Menopausal Hot Flashes Market Key Driver
Government initiatives for women's health in menopause are driving the growth of the menopausal hot flashes market, with the Government of New South Wales allocating $40.3 million for women's health programs. These initiatives aim to support women facing severe menopausal symptoms, boosting the demand for treatments and therapies for hot flashes.
Get A Free Sample Of The Global Menopausal Hot Flashes Market ReportGlobal Menopausal Hot Flashes Market Segments
The menopausal hot flashes market covered in this report is segmented –
1) Type:Hormonal Treatment, Non-hormonal Treatment, Alternative Treatment
2) Pipeline Analysis:Phase III Drugs, Phase I and II Drugs
3) Distribution Channel:Retail Pharmacies, Online Pharmacies, Hospital Pharmacies
4) Application:51-55 Year Old Woman, 46-50 Year Old Woman, 40-45 Year Old Woman
By Geography: The countries covered in the menopausal hot flashes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the Menopausal Hot Flashes market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menopausal hot flashes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Menopausal Hot Flashes Industry Players
Pfizer Inc.; Johnson & Johnson; The Procter & Gamble Company; Merck & Co. Inc.; Bayer AG; Novartis AG; AstraZeneca plc; GlaxoSmithKline plc.; Takeda Pharmaceutical Company Limited; Eli Lilly and Co Ltd.; Novo Nordisk A/S; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Eisai Co. Ltd.; Otsuka Pharmaceutical Co. Ltd.; Shionogi & Co. Ltd.; Gedeon Richter Plc; Lupin Limited; Hisamitsu Pharmaceutical Co. Inc.; Noven Pharmaceuticals Inc.; Ligand Pharmaceuticals Inc.; Mithra Pharmaceuticals SA; TherapeuticsMD Inc.; Theramex Ltd.; Ascend Therapeutics Inc.; EndoCeutics Inc.; Sermonix Pharmaceuticals LLC; Ralington pharma LLP; Bionovo Inc.
Get The Full Global Menopausal Hot Flashes Market Report
Menopausal Hot Flashes Market Overview
Menopausal hot flashes, also known as vasomotor symptoms, are common menopausal and perimenopausal symptoms that can occur as an intense burst of heat, sweating, and heated skin in women. Hot flashes can be irritating and unpleasant, causing discomfort, anxiety, and sleep disruption.